Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Atezolizumab + Bevacizumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 106 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov).
Bevacizumab Avastin VEGF Antibody 10 VEGFR Inhibitor (Pan) 35 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04102098 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT04487067 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA) Active, not recruiting ITA 0
NCT03896074 Phase II Atezolizumab + Bevacizumab Atezolizumab Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) Unknown status ITA 0
NCT05180006 Phase II Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) Recruiting FRA 0
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Active, not recruiting USA 0
NCT04803994 Phase III Atezolizumab + Bevacizumab The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma Recruiting ESP | DEU 0
NCT04931342 Phase II Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT03434379 Phase III Atezolizumab + Bevacizumab Sorafenib A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT04727307 Phase II Atezolizumab + Bevacizumab Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02) Recruiting FRA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT05185505 FDA approved Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria Recruiting USA 0
NCT03818061 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA) Active, not recruiting FRA 0
NCT04356729 Phase II Atezolizumab + Bevacizumab A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Recruiting USA 0
NCT04486352 Phase Ib/II Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) Recruiting USA 0
NCT03424005 Phase Ib/II Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) Active, not recruiting USA | GBR | FRA | ESP | DEU | AUS 2
NCT05665348 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Ipilimumab Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) Not yet recruiting FRA 0
NCT03526432 Phase II Atezolizumab + Bevacizumab Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer Active, not recruiting USA 0
NCT05717400 FDA approved Atezolizumab + Bevacizumab Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Not yet recruiting USA 0
NCT04732286 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy Active, not recruiting ESP 0
NCT05620771 Phase II Yttrium-90 microsphere therapy Atezolizumab + Bevacizumab Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk Recruiting USA 0
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Completed USA | AUS 5
NCT04857684 Phase I Atezolizumab + Bevacizumab SBRT + Atezolizumab + Bevacizumab in Resectable HCC Recruiting USA 0
NCT04721132 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Recruiting USA 0
NCT04099836 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Active, not recruiting USA 0
NCT04541173 Phase II Atezolizumab + Bevacizumab Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04524871 Phase Ib/II Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) Recruiting USA | FRA 5
NCT05488522 Phase I Atezolizumab + Bevacizumab SBRT With Atezo/Bev for HCC Recruiting USA 0
NCT02921269 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Completed USA 0
NCT05063552 Phase II Bevacizumab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Bevacizumab + Carboplatin + Docetaxel Cetuximab + Cisplatin + Docetaxel Atezolizumab + Bevacizumab Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Recruiting USA 0
NCT04510584 Phase II Atezolizumab + Bevacizumab Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer Recruiting CAN 0
NCT05537402 Phase II Atezolizumab + Bevacizumab LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial (LOST-B) Not yet recruiting USA 0
NCT03272217 Phase II Atezolizumab + Bevacizumab Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Terminated USA 0
NCT05482516 Phase III Atezolizumab + Bevacizumab Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) Recruiting USA 0
NCT04739202 Phase II Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST) Recruiting FRA 0
NCT03175432 Phase II Atezolizumab + Bevacizumab Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) Recruiting USA 0
NCT05096715 Phase I Atezolizumab + Bevacizumab Atezolizumab+Bevacizumab+SBRT in Unresectable HCC Not yet recruiting USA 0
NCT04829383 Phase II Atezolizumab + Bevacizumab A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) Recruiting USA 0
NCT04563338 Phase II Atezolizumab Atezolizumab + Bevacizumab An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) Recruiting CAN 0
NCT05690048 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Fecal microbiota + Vancomycin Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA) Not yet recruiting DEU 0
NCT02982694 Phase II Atezolizumab + Bevacizumab Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Terminated ITA | ESP | BEL 1
NCT05359861 Phase II Atezolizumab + Bevacizumab + SRF388 Atezolizumab + Bevacizumab Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma Recruiting USA | AUS 2
NCT05528952 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + UCPVax Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO) Recruiting FRA 0
NCT05448677 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + GNS561 Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER) Recruiting FRA 0
NCT03654833 Phase II Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) Active, not recruiting GBR 0


Additional content available in CKB BOOST